Navigation Links
New diagnostic advance seen for head, throat cancer

CORVALLIS, Ore. Pharmacy researchers at Oregon State University today announced the discovery of a genetic regulator that is expressed at higher levels in the most aggressive types of head and neck cancers, in work that may help to identify them earlier or even offer a new therapy at some point in the future.

This "transcriptional regulator" is called CTIP2, and in recent research has been demonstrated to be a master regulator that has important roles in many biological functions, ranging from the proper development of enamel on teeth to skin formation and the possible treatment of eczema or psoriasis.

In the newest study, published today in PLoS ONE, a professional journal, scientists found for the first time that levels of CTIP2 were more than five times higher in the "poorly differentiated" tumor cells that caused the most deadly types of squamous cell carcinomas in the larynx, throat, tongue and other parts of the head. There was a high correlation between greater CTIP2 expression and the aggressive nature of the cancer.

Head and neck squamous cell cancers are the sixth most common cancers in the world, the researchers said in their study, and a significant cause of mortality. In 2008, cancers of the oral cavity and pharynx alone accounted for 35,310 new cases in the United States and 7,590 deaths. They have been linked to such things as tobacco use and alcohol consumption.

"Serious head and throat cancer is pretty common, and mortality rates from it haven't improved much in 20 years, despite new types of treatments," said Gitali Indra, an assistant professor in the OSU College of Pharmacy. "With these new findings, we believe it should be possible to create an early screening and diagnostic tool to spot these cancers earlier, tell physicians which ones need the most aggressive treatments and which are most apt to recur."

It's also possible the work may lead to new therapeutic approaches, researchers say.

"It's not completely clear yet whether the higher levels of CTIP2 expression are a consequence of cancer, or part of the cause," said Arup Indra, also an OSU assistant professor of pharmacy. "However, we strongly suspect that it's causally related. If that's true, then therapies that could block production of CTIP2 may provide a new therapeutic approach to this type of cancer."

That this genetic regulator could be involved in both skin development and these types of cancer makes some sense, the scientists said both originate from epithelial cells.

It's also possible, the study found, that CTIP2 works to help regulate the growth of what is believed to be a cancer "stem" or "progenitor" cell, which has a greater potential to generate tumors through the stem cell processes of self-renewal and differentiation into multiple cell types. Therefore, targeting cancer stem cells holds promise for improvement of survival and quality of life of cancer patients.


Contact: Gitali Indra
Oregon State University

Related biology news :

1. InVitria Announces Launch of Recombinant Albumin for Diagnostics
2. Major step for drug discovery and diagnostics
3. Arbor Vita presents new data on cancer diagnostic at EUrogin
4. European researchers harness unique properties of boron to develop new drugs and diagnostics
5. Genetic Engineering & Biotechnology News reports on growing role of molecular diagnostics
6. AACR hosts Molecular Diagnostics in Cancer Therapeutic Development Meeting
7. New electrostatic-based DNA microarray technique could revolutionize medical diagnostics
8. Fluorescent nano-barcodes could revolutionize diagnostics
9. First diagnostic test for Alzheimers and Parkinsons disease on the horizon
10. Arbor Vita rapid H5N1 flu diagnostic presented at ICEID meeting
11. Smiths Detection to launch a portable diagnostic system for foot-and-mouth disease and avian flu
Post Your Comments:
(Date:10/2/2015)... 2015 ) ... the Law Using Biometrics" report to their ... the addition of the "Enforcing the Law ... --> Research and Markets ( ) ... the Law Using Biometrics" report to their ...
(Date:9/30/2015)... Sept. 30, 2015  The global glucose monitoring device and ... So says a new report on the industry from Kalorama ... dominate the market, followed by continuous glucose monitoring and sensor ... the market for these products in its latest report, ... , ...
(Date:9/28/2015)... 28, 2015  The monitoring of vital signs, ... temperature, is an essential component of patient assessment. ... deterioration in a patient,s condition. However, in general ... typically taken during routine observation rounds only once ... deteriorates between these observation rounds, the warning signs ...
Breaking Biology News(10 mins):
(Date:10/13/2015)... ... 2015 , ... The Pistoia Alliance has appointed Dr Steve ... drive to increase the organization’s impact on the global innovation landscape in life ... its work in supporting pre-competitive collaboration in the life sciences sector. Steve brings ...
(Date:10/13/2015)... Applied BioMath ( ), a computational ... the drug invention process, announced that it will sponsor ... 20-22, 2015 in Boston , MA.  ... CEO of Applied BioMath, will present "QSP approaches enabling quantitative ... trials" on Wednesday October 21st 2015 at 12:30PM.  ...
(Date:10/13/2015)... ARRY ), Avanex Life Sciences ... ), and Progenix Pharmaceuticals, Inc. (NASDAQ: PGNX ) ... (OTCQX: AVXLD), Juno Therapeutics, Inc. (NASDAQ: JUNO ), ... --> Cooperative research and development efforts with the ... to advancements in the treatment of severe wounds.  Biotech ...
(Date:10/13/2015)... and SAN DIEGO , ... Mast Therapeutics, Inc. have agreed to collaborate in the ... poloxamer 188 NF, marketed by BASF under the Kolliphor ... a variety of pharmaceutical and biological applications, such as ... is the starting material for Mast,s lead product candidate. ...
Breaking Biology Technology: